Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
CCORF Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $20
J.P. Morgan Maintains Stoke Therapeutics(STOK.US) With Hold Rating, Raises Target Price to $15
Stoke Therapeutics Shares Are Trading Higher on Possible Continued Strength Following Q3 Reported Financial Results Yesterday. Also, Needham and HC Wainwright & Co. Reiterated Buy Ratings on the Stock.
A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $15 to $35
Analysts Conflicted on These Healthcare Names: AnaptysBio (ANAB), Stoke Therapeutics (STOK) and Immatics (IMTX)